GT Biopharma Statistics
Total Valuation
GT Biopharma has a market cap or net worth of $11.54 million. The enterprise value is $2.62 million.
| Market Cap | 11.54M |
| Enterprise Value | 2.62M |
Important Dates
The next estimated earnings date is Friday, August 14, 2026, after market close.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GT Biopharma has 36.06 million shares outstanding. The number of shares has increased by 484.42% in one year.
| Current Share Class | 36.06M |
| Shares Outstanding | 36.06M |
| Shares Change (YoY) | +484.42% |
| Shares Change (QoQ) | +133.34% |
| Owned by Insiders (%) | 6.94% |
| Owned by Institutions (%) | 6.08% |
| Float | 33.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.49 |
| P/TBV Ratio | 1.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.14
| Current Ratio | 4.14 |
| Quick Ratio | 3.69 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -70.20 |
Financial Efficiency
Return on equity (ROE) is -921.55% and return on invested capital (ROIC) is -252.61%.
| Return on Equity (ROE) | -921.55% |
| Return on Assets (ROA) | -131.76% |
| Return on Invested Capital (ROIC) | -252.61% |
| Return on Capital Employed (ROCE) | -175.96% |
| Weighted Average Cost of Capital (WACC) | 9.21% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$37.04M |
| Employee Count | 1 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -81.60% in the last 52 weeks. The beta is 0.90, so GT Biopharma's price volatility has been similar to the market average.
| Beta (5Y) | 0.90 |
| 52-Week Price Change | -81.60% |
| 50-Day Moving Average | 0.41 |
| 200-Day Moving Average | 0.52 |
| Relative Strength Index (RSI) | 42.51 |
| Average Volume (20 Days) | 639,393 |
Short Selling Information
The latest short interest is 4.78 million, so 13.27% of the outstanding shares have been sold short.
| Short Interest | 4.78M |
| Short Previous Month | 3.42M |
| Short % of Shares Out | 13.27% |
| Short % of Float | 14.30% |
| Short Ratio (days to cover) | 3.54 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -13.34M |
| Pretax Income | -30.41M |
| Net Income | -37.04M |
| EBITDA | -13.34M |
| EBIT | -13.34M |
| Earnings Per Share (EPS) | -$2.96 |
Balance Sheet
The company has $8.92 million in cash and no debt, with a net cash position of $8.92 million or $0.25 per share.
| Cash & Cash Equivalents | 8.92M |
| Total Debt | n/a |
| Net Cash | 8.92M |
| Net Cash Per Share | $0.25 |
| Equity (Book Value) | 7.58M |
| Book Value Per Share | 0.22 |
| Working Capital | 7.58M |
Cash Flow
| Operating Cash Flow | -13.18M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -13.18M |
| FCF Per Share | -$0.37 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GT Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -484.42% |
| Shareholder Yield | -484.42% |
| Earnings Yield | -320.88% |
| FCF Yield | -114.17% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 5, 2024. It was a reverse split with a ratio of 1:30.
| Last Split Date | Feb 5, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |